Indapamide to slow worsening of disability in progressive multiple sclerosis
Tests indapamide in adults with primary or secondary progressive multiple sclerosis.
Key facts
- Who runs it
- Amsterdam UMC Stichting
- Where
- Amsterdam, NetherlandsSee the site
- Trial code
- Registry title
- Use of Indipamide to reduce progression of disability in people with primary and secondary progressive multiple sclerosis (MS).
- Status
- Recruiting
- Phase
- Phase 2
- People taking part
- 84 people, planned
- Started
- 25 Sept 2026
- Expected to end
- 30 Jun 2028
- Type of study
- Interventional
- Record updated
- 8 July 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with primary or secondary progressive multiple sclerosis who have moderate walking disability, to test oral indapamide.
- Age
- 18 to 65 years
- Sex
- All sexes
- Disease stage
- Primary progressive (PPMS) or secondary progressive (SPMS) multiple sclerosis. Expanded Disability Status Scale score between 4.0 and 6.5. Timed 25 foot walk of 5 seconds or more (PPMS) or 9 seconds or more (SPMS).
- Earlier treatment
- Cannot be using siponimod, ocrelizumab, natalizumab or other treatment for relapsing-remitting MS. Cannot be using corticosteroids, Fampridine or 4-aminopyridine.
Main reasons for not taking part
- Kidney problems with eGFR below 30ml/min per 1.73 m2
- Recent gadolinium enhancement or new T2 lesions on MRI in the 6 months before joining
- Heart rhythm problems or a long QT interval
- Serious liver problems
- Pregnant or breast-feeding, or allergic to indapamide
The registry criteria, word for word
Show all 21 criteriaShow less
Who can take part
- Written informed consent obtained
- Aged between 18 and 65 years
- Diagnosed with PPMS or SPMS, according to current diagnostic criteria
- Screening Expanded Disability Status Scale score between 4.0 and 6.5 inclusive
- Screening timed 25 foot walk (average of two trials) of 5 seconds or more for people with PPMS, or of 9 seconds or more for people with SPMS
- Use of effective methods of contraception for women of childbearing potential
Who cannot take part
- Individuals who receive treatment with Botulinum toxin in the leg muscles during the trial
- Individuals with recent gadolinium enhancement or new T2 lesions on brain/spinal cord MRI in the 6 months prior to inclusion
- Concomitant use of corticosteroids
- Individuals who use siponimod, ocrelizumab, natalizumab or other disease-modifying treatment for RRMS
- Individuals with significant hepatic impairment (pre-existing or developing during the trial)
- Individuals with cardiac arrhythmia
- Individuals with an allergy or other intolerability to indapamide
- Individuals with renal insufficiency and an eGFR below 30ml/min per 1.73 m2
- Individuals with a prolonged QT interval: individuals with frequency corrected QT (QTc) intervals of more than 450ms (men) or 470ms (women) at the screening examination will not be included in the study, and participants with QTc intervals of greater than 500ms on any of the other ECG examinations throughout the study will be excluded from the study
- Individuals who start Baclofen or Tizanidine during the trial
- Individuals who increase the dose of Baclofen or Tizanidine during the trial
- Individuals with clinically significant abnormal screening labs
- Individuals who are pregnant or currently breast-feeding
- Individuals who use Fampridine or 4-aminopyridine
- Individuals who start Fampridine or 4-aminopyridine during the trial
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 64 years old?
Where in Netherlands
- Amsterdam UMC StichtingAmsterdam, NetherlandsTaking people
About the trial
What the trial wants to find out
To demonstrate non-futility of indapamide treatment for the prevention of disability worsening in PPMS and SPMS
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record
Print a page for my doctorSaves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Official title
- Open-label, single-center, single-arm phase 2 futility trial evaluating the oral indapamide for reducing progression of disability in people with primary and secondary progressive multiple sclerosis (MS)
- Plain-language title
- Indapamide to slow worsening of disability in progressive multiple sclerosisGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 9 November 2026.
- Fit questions
- Built from 2026-525260-18-00, who can take part
- Record updated
- 8 July 2026